Sean Murphy

TriSalus Operating Life Sciences, Inc. develops infusion systems for the interventional radiology and oncology markets. Its infusion systems are designed to deliver embolic agents through a micro-catheter with an expandable tip that collapses in forward flow and expands the vessel wall in reverse flow to increase targeted delivery, minimize reflux, and reduce damage to healthy tissue. The company was founded by Aravind Arepally and James E. Chomas in 2011 and is headquartered in Westminster, CO.

Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC.

TriSalus Operating Life Sciences, Inc. develops infusion systems for the interventional radiology and oncology markets. Its infusion systems are designed to deliver embolic agents through a micro-catheter with an expandable tip that collapses in forward flow and expands the vessel wall in reverse flow to increase targeted delivery, minimize reflux, and reduce damage to healthy tissue. The company was founded by Aravind Arepally and James E. Chomas in 2011 and is headquartered in Westminster, CO.

The American company is devoted to ushering in a new era of precision medicine in acute care. Prenosis' immunix™ precision diagnostics and evidence generation platform leverages machine learning algorithms trained on deep biological data and broad clinical data designed to capture and illuminate the complex health states of patients more holistically. The company's proprietary dataset is one of the largest and fastest-growing hybrid biomarker-clinical datasets for sepsis care. Prenosis enables physicians, providers, payers, and pharma to understand patients' unique biology and see people differently. The company was founded by Bobby Reddy and Rashid Bashir, and Bobby Reddy has been the CEO since incorporation.

Brandon Point Industries Ltd. operates as a life sciences company. It focuses on healthcare. The company was founded in 2014 by George Kelly Martin and John Oliver Thomas Given and is headquartered in Dublin, Ireland.

Part of Ethypharm SAS, Altan Pharma Ltd. is an Irish company that develops, manufactures, and markets injectable medications. The private company is based in Dublin, Ireland. The company was founded in 1998 by Guillermo A. Herrera. Guillermo A. Herrera has been the CEO since 1998. Altan Pharma was acquired by Ethypharm SAS from Malin Corp. Plc on October 01, 2021.

Part of Malin Corp. Plc, Malin Life Sciences Holdings Ltd. functions as an investment holding Irish company. The private company is based in Dublin, Ireland. The CEO of the company is George Kelly Martin.

Part of Ethypharm SAS, Altan Pharma Ltd. is an Irish company that develops, manufactures, and markets injectable medications. The private company is based in Dublin, Ireland. The company was founded in 1998 by Guillermo A. Herrera. Guillermo A. Herrera has been the CEO since 1998. Altan Pharma was acquired by Ethypharm SAS from Malin Corp. Plc on October 01, 2021.

The American company is devoted to ushering in a new era of precision medicine in acute care. Prenosis' immunix™ precision diagnostics and evidence generation platform leverages machine learning algorithms trained on deep biological data and broad clinical data designed to capture and illuminate the complex health states of patients more holistically. The company's proprietary dataset is one of the largest and fastest-growing hybrid biomarker-clinical datasets for sepsis care. Prenosis enables physicians, providers, payers, and pharma to understand patients' unique biology and see people differently. The company was founded by Bobby Reddy and Rashid Bashir, and Bobby Reddy has been the CEO since incorporation.

TriSalus Operating Life Sciences, Inc. develops infusion systems for the interventional radiology and oncology markets. Its infusion systems are designed to deliver embolic agents through a micro-catheter with an expandable tip that collapses in forward flow and expands the vessel wall in reverse flow to increase targeted delivery, minimize reflux, and reduce damage to healthy tissue. The company was founded by Aravind Arepally and James E. Chomas in 2011 and is headquartered in Westminster, CO.

Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC.

Xenex Disinfection Services, Inc. provides ultraviolet room disinfection systems for healthcare facilities. The firm's patented pulsed xenon UV room disinfection system is a pesticidal device used for the advanced cleaning of healthcare facilities and due to its speed and ease of use, the Xenex system has proven to integrate smoothly into hospital cleaning operations. The company eliminates harmful bacteria, viruses and spores that can cause hospital acquired infections in the patient environment, and to become the new standard method for disinfection in healthcare facilities worldwide. The company was founded by Julie A. Stachowiak, Brian Cruver and Mark Stibich in August 2008 and is headquartered in San Antonio, TX.

Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC.

Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC.

Xenex Disinfection Services, Inc. provides ultraviolet room disinfection systems for healthcare facilities. The firm's patented pulsed xenon UV room disinfection system is a pesticidal device used for the advanced cleaning of healthcare facilities and due to its speed and ease of use, the Xenex system has proven to integrate smoothly into hospital cleaning operations. The company eliminates harmful bacteria, viruses and spores that can cause hospital acquired infections in the patient environment, and to become the new standard method for disinfection in healthcare facilities worldwide. The company was founded by Julie A. Stachowiak, Brian Cruver and Mark Stibich in August 2008 and is headquartered in San Antonio, TX.

The American company is devoted to ushering in a new era of precision medicine in acute care. Prenosis' immunix™ precision diagnostics and evidence generation platform leverages machine learning algorithms trained on deep biological data and broad clinical data designed to capture and illuminate the complex health states of patients more holistically. The company's proprietary dataset is one of the largest and fastest-growing hybrid biomarker-clinical datasets for sepsis care. Prenosis enables physicians, providers, payers, and pharma to understand patients' unique biology and see people differently. The company was founded by Bobby Reddy and Rashid Bashir, and Bobby Reddy has been the CEO since incorporation.

The American company is devoted to ushering in a new era of precision medicine in acute care. Prenosis' immunix™ precision diagnostics and evidence generation platform leverages machine learning algorithms trained on deep biological data and broad clinical data designed to capture and illuminate the complex health states of patients more holistically. The company's proprietary dataset is one of the largest and fastest-growing hybrid biomarker-clinical datasets for sepsis care. Prenosis enables physicians, providers, payers, and pharma to understand patients' unique biology and see people differently. The company was founded by Bobby Reddy and Rashid Bashir, and Bobby Reddy has been the CEO since incorporation.

The American company is devoted to ushering in a new era of precision medicine in acute care. Prenosis' immunix™ precision diagnostics and evidence generation platform leverages machine learning algorithms trained on deep biological data and broad clinical data designed to capture and illuminate the complex health states of patients more holistically. The company's proprietary dataset is one of the largest and fastest-growing hybrid biomarker-clinical datasets for sepsis care. Prenosis enables physicians, providers, payers, and pharma to understand patients' unique biology and see people differently. The company was founded by Bobby Reddy and Rashid Bashir, and Bobby Reddy has been the CEO since incorporation.